Dr. Hui-Ju Ch’ang —Research Field




As a radiation oncologists, Dr. Ch’ang is interested in clinical radiation as well as modern radiation biology of hepatobilliary and gastrointestinal malignancies. Her laboratory work is majoring in the contribution of bone marrow stem cells in intestinal repair after radiation. Similar studies are developed for studying bone marrow stem cells with tumor microenvironment after radiation. She is also interested in investigating combination effect of molecular targeting agents and radiation. Besides animal studies, she designed clinical studies for hepatocellular carcinoma patients undergoing local radiation. The blood perfusion within tumor was measured by dynamic contrast enhanced magnetic resonance imaging before, during and after radiation treatment course. A series of clinical trials for pancreatic cancer patients were also initiated by Dr. Ch’ang in collaboration with Professor Li-Tzong Chen.


Professional Activities:

A. Principle Investigator, National Health Research Institutes

  1. De Novo Ceramide Synthesis Pathway in the Evolution of Radiation-Induced GI Syndrome (NHRI 2002)
  2. Influence of Bone Marrow on Radiation Induced Gastrointestinal Damage (NHRI 2003)
  3. A Phase II Study of Postoperative Local Irradiation plus Oral Thalidomide in Glioblastoma Multiforme (NHRI 2003-2005)
  4. The role of Mesenchymal-Epithelial Interaction in Radiation InducedIntestinal Mucosa Damage Repair (NHRI 2004~2006)
  5. A Phase II Study of Induction Chemotherapy followed by Concurrent Chemotherapy with Radiotherapy in Locally Advanced Pancreatic Cancer (NHRI 2004~2009)
  6. A Pilot Clinical and Mechanistic Study of Radiotherapy plus Thalidomide for Locally Advanced Hepatocellular Carcinoma (HCC) (NHRI 2004~2009)
  7. Mobilization of Bone Marrow Stem Cells and Cancer Cells by Granulocyte Colony-Stimulating Factor in Cancer Therapy (NHRI 2007~2010)
  8. Bone Marrow Enhances Intestinal Stromal Cell Proliferation and Protects Intestine from Radiation Damage Through Paracrine Mechanism (NSC2008-2010)
  9. A randomized phase III study of adjuvant gemcitabine versus gemcitabine plus concurrent chemoradiation in pancreatic cancer underwent curative intent (R0/R1) (2008~)
  10. The Clinical Significance of VEGF and SDF-1/CXCR4 Signaling Pathway Biomarkers in Patients with Pancreatic Cancer (DOH2008~2009)
  11. A Phase II Randomized Study of Induction Chemotherapy followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer (NHRI 2010~)
  12. Molecular Mechanisms of Shear Stress in Regulating Cellular Radiation Sensitivity (NHRI 2010~2011)
  13. Molecular Mechanisms of Shear Stress in Regulating Cellular Radiation Sensitivity of Pancreatic Carcinoma (NHRI 2011~2014)
  14. Fusion between Bone Marrow and Intestine Stromal Cells Contributes to Intestine Fibrosis after Radiation (NSC 2011/8-2012/7)
  15. Strategies Targeting Fusion Machinery of Bone Marrow Derived Macrophage May Ameliorate Intestinal Fibrosis after Radiation (NSC 2012/8-2015/7)
  16. Study the Klf10 alters metabolic pathways in genetic-deficient mice and human pancreatic ductal carcinoma. (NSC 2012/8-2014/7)
  17. Molecular Mechanisms of Krüpple like factor 10 in Regulating
  18. Pancreatic Cancer Progression and Radiation Sensitivity (NSC 2015/8-2018/7)
  19. The role of cell fusion between macrophage and cancer cells in pancreatic cancer progression after radiation (NHRI 2015~2018)

B. Research Fellow, Memorial Sloan-Kettering Cancer Center, Laboratory of Radiation Research in 2000

  1. De Novo Synthesis of Ceramide in Mitochondria after Radiation of HeLa Cells
  2. Role of Ceramide Synthase in Radiation Hyperensitivity of ATM Knock Out Mice.

C. Research Fellow, NHRI (National Health Research Institutes), TCOG (Taiwan Cooperative Oncology Group) Laboratory, Urine Therapy Study in 1998:

  1. Reversal of Drug Resistance in Breast Cancer Cells by Human Urine Extract

D. Study Coordinator, SYSCC Cancer Study Protocol in 1995:

  1. Preoperative concurrent chemotherapy and radiotherapy in rectal cancer patients.
  2. Postoperatve concurrent chemotherapy and radiotherapy for resectable locally advanced gastric cancer patients.
Share Button

Comments are closed.